Among the anti-VEGF class events, hypertension was the most commonly reported G3–4 AE both in our study and in VELOUR trial, affecting 18.4% and 19.3% of patients, respectively [12] (Table 8). The gene discussed is VEGFA; the disease is Hypertension.